key: cord-0830056-39saijjp authors: Horowitz, Richard I.; Freeman, Phyllis R. title: Three Novel Prevention, Diagnostic and Treatment Options for COVID-19 Urgently Necessitating Controlled Randomized Trials date: 2020-05-22 journal: Med Hypotheses DOI: 10.1016/j.mehy.2020.109851 sha: ffe1951b4290fb8612750822753d08cdb19e09e6 doc_id: 830056 cord_uid: 39saijjp PURPOSE: Asymptomatic or minimally symptomatic infection with COVID-19 can result in silent transmission to large numbers of individuals, resulting in expansion of the pandemic with a global increase in morbidity and mortality. New ways of screening the general population for COVID-19 are urgently needed along with novel effective prevention and treatment strategies. HYPOTHESIS: A hypothetical three-part prevention, diagnostic, and treatment approach based on an up-to-date scientific literature review for COVID- 19 is proposed. Regarding diagnosis, a validated screening questionnaire and digital app for COVID-19 could help identify individuals who are at risk of transmitting the disease, as well as those at highest risk for poor clinical outcomes. Global implementation and online tracking of vital signs and scored questionnaires that are statistically validated would help health authorities properly allocate essential health care resources to test and isolate those at highest risk for transmission and poor outcomes. Second, regarding prevention, no validated protocols except for physical distancing, hand washing, and isolation exist, and recently ivermectin and the antimalarial drugs chloroquine and hydroxychloroquine has been published to have anti-viral properties against COVID-19. A randomized trial of ivermectin or hydroxychloroquine alone, and/or nutraceuticals that have been published to support immune function including Vitamin C, zinc, and immunomodulatory supplements (3,6 Beta glucan) could be beneficial in preventing transmission or lessening symptomatology but requires statistical validation. Third, concerning treatment, COVID-19 induced inflammation and “cytokine storm syndrome” with hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) have resulted in extreme morbidity and mortality in those with certain comorbidities, secondary to “acute respiratory distress syndrome” (ARDS) and multiorgan dysfunction with disseminated intravascular coagulation (DIC). Deficiency in red blood cell, serum and alveolar glutathione has been published in the medical literature for ARDS, as well as viral and bacterial pneumonias, resulting from increased levels of free radical/oxidative stress. A randomized controlled trial of blocking NFKappa B and cytokine formation using glutathione precursors (N-acetyl-cysteine [NAC] and alpha lipoic acid) and PO/IV glutathione should be performed, along with an evaluation of Nrf2 activators (curcumin, sulforaphane glucosinolate) which have been scientifically proven to lower inflammation. Since high mortality rates from sepsis induced DIC due to COVID 19 infection has also been associated with thrombotic events and elevated levels of D-dimer, randomized controlled trials of using anticoagulant therapy with heparin is urgently required. This is especially important in patients on ventilators who have met certain sepsis induced coagulopathy (SIC) criteria. The use of acetazolamide with or without sildenafil also needs to be explored with or without heparin, since increased oxygen delivery to vital organs through prevention of thrombosis/pulmonary emboli along with carbonic anhydrase inhibition may help increase oxygenation and prevent adverse clinical outcomes. CONCLUSION AND IMPLICATIONS: a three-part prevention, diagnostic, and treatment plan is proposed for addressing the severe complications of COVID-19. Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; prevention with hydroxychloroquine and/or ivermetin as well as nutritional therapies that support a healthy immune response; treatment with anti-inflammatory therapies that block NFKappaB and activate Nrf2 pathways, as well as novel therapies that address COVID-19 pneumonia and ARDS with DIC including anticoagulation and/ or novel respiratory therapies with or without acetazolamide and sildenafil. These three broad-based interventions urgently need to be subjected to randomized, controlled trials. . The disease may result in a broad range of clinical manifestations, ranging from asymptomatic infection to severe ARDS and respiratory failure with death 3 . Those at highest risk for adverse outcomes includes advanced age, male gender 4 , race (African-American) 5 , obesity 6 , smoking history 7 , and prior medical histories including hypertension, diabetes, cardiovascular and respiratory disease (asthma, emphysema) 5 , hemorrhagic or ischemic strokes, immunosuppression, cancer, chronic kidney and liver disease as well as those with secondary infections 8 9 . More than 100,000 people have died worldwide in the covid-19 pandemic as of April 10, 2020 according to recent data from Johns Hopkins University 10 . As of April 11, 2020 almost 1.7 million people worldwide have been infected 11 with global mortality rates over time leveling off to a higher rate of 5.7% converging with current WHO estimates 12 . Finding practical solutions for reducing transmission and mitigating the high morbidity and mortality rates from COVID 19 is urgently needed. Early prodromal symptoms can include hyposmia, anosmia and dyguesia 13 followed by a fever, sore throat, cough, chest tightness and shortness of breath 14 . Other symptoms may include a conjunctivitis, headaches and myalgias 15 as well as gastrointestinal symptoms of nausea, vomiting, abdominal discomfort, and diarrhea 16 . Rarely a productive cough and hemoptysis may result 9 . Severe complications include Novel Coronavirus Pneumonia (NCP) with or without acute respiratory distress syndrome (ARDS) and respiratory failure, organ function damage with cardiac injury and fulminate myocarditis 17 , acute kidney injury, liver dysfunction, and pneumothorax 18 . ARDS is however the main cause of death in COVID-19 9 and the fundamental pathophysiology underlying many of the above complications is "cytokine storm syndrome" 19 . This results from an uncontrolled systemic inflammatory response releasing large amounts of pro-inflammatory cytokines (IFN-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TNF-α, TGFβ, etc.) as well as chemokines (CXCL9, CXCL10, etc.) by immune effector cells 20 . Secondary hemophagocytic lymphohistiocytosis (sHLH), also known as macrophage activation syndrome (MAS), can similarly result 19 . This is a hyperinflammatory syndrome characterized by a fulminant and fatal hypercytokinemia with multiorgan failure, previously noted in approximately 4% of cases triggered by viral infections 21 and/or sepsis 22 . Cardinal features of sHLH/MAS include unremitting fever, cytopenia's, low or absent natural killer (NK) cell activity, hepatosplenomegaly, hepatobiliary dysfunction (HBD), coagulopathy, high ferritin levels (≥500 ng/ml), fasting triglycerides ≥265 mg/dl with fibrinogen levels ≤150 mg/dl; as well pulmonary involvement with ARDS which can occur in up to 50% of patients 19 23 . This same constellation of symptoms and laboratory abnormalities can be seen in those with fatal complications from COVID-19 19 . Macrophage activating syndrome (MAS) has been previously reported in autoimmune disorders and infections which are primarily of viral origin. Pathogenesis is associated with increased activation of macrophages and NK cells 24 , where an autocrine loop of interleukin (IL)-1β over-secretion leads to cytokine storm of IL-6, IL-18, ferritin, and interferon-gamma 22 ; High ferritin levels have been proposed to be the diagnostic hallmark of MAS, and ferritin measurements within the first 24 hours can be used as a diagnostic biomarker of MAS 25 26 . Among the cytokines produced, Interleukin-18 also has been shown to diagnostically distinguish and pathogenically promote human and murine macrophage activation syndrome 27 . Among pulmonary involvement in patients with HLH/MAS, dyspnea and cough were the most common symptoms at the onset of the disease, and radiographs revealed interstitial infiltrates with centrilobular nodules, ill-defined consolidation, or localized ground-glass opacities 23 . These are some of the same radiological abnormalities seen in patients who recovered from COVID-19 pneumonia, where initial lung findings on chest CT revealed small subpleural ground glass opacities (GGO) that grew larger with crazy-paving pattern and consolidation up to two weeks after disease onset, eventually being absorbed resulting in extensive GGO and subpleural parenchymal bands 28 . The sickest patients admitted to the intensive care units (ICUs) in the United States with COVID-19 pneumonia have been those with ARDS, hypoxemic respiratory failure leading to mechanical ventilation, and/or hypotension requiring vasopressor treatment 29 . The mortality rates of patients on ventilators has been extremely high 29 , and compared with non-ICU patients, one recent Chinese study showed that ICU patients all presented with pneumonia, had higher plasma levels of cytokines including TNFα, IL-2, IL-7, IL-10 and shared common complications including acute cardiac injury, secondary infections and ARDS 9 . The pathophysiology underlying critical cases of viral pneumonia is often severe ARDS 30 . ARDS is caused by lung inflammation and increased alveolar endothelial and epithelial permeabilities 30 resulting in a protein-rich pulmonary edema with severe hypoxemia and impaired carbon dioxide excretion 31 . The lung injury is primarily due to neutrophil-dependent and platelet-dependent damage to the endothelial and epithelial barriers of the lung, frequently caused by pneumonia 31 Neutrophils can become activated, leading to the release of toxic mediators including reactive oxygen species (ROS), proinflammatory cytokines and procoagulant molecules 31 , where further synergistic interaction with platelets increase damage to the lungs 32 . A procoagulant effect with coagulopathy and anti-phospholipid antibodies has recently been reported in patients with Covid-19 33 , and these abnormal coagulation parameters have been shown to be associated with a poorer prognosis in patients with novel coronavirus pneumonia (NCP) 34 . It is therefore important to find ways to decrease free radical oxidative stress (ROS), high levels of inflammatory cytokines and procoagulant pathways triggered by COVID-19 if we are to impact the high morbidity and mortality rates associated with the disease process. Lack of adequate antioxidant protection in the setting of high levels of ROS may therefore play an important role in damaging the lungs. Prior published reports have shown that the alveolar epithelial lining fluid of patients with ARDS is deficient in total glutathione (GSH) compared to normal subjects, and glutathione is one of the master anti-oxidants in the body 35 . GSH measured in unconcentrated bronchoalveolar lavage (BAL) fluid in those with ARDS also showed that there was a deficiency in patients with ARDS compared to normal subjects. In this setting, reactive oxygen species such as hydrogen peroxide may play a key role in the pathogenesis of the acute lung injury with ARDS 35 . Based on the above clinical and biochemical abnormalities post viral exposure to COVID-19, and high levels of infectivity, morbidity and mortality, we propose a novel three-part prevention, diagnostic, and treatment plan to help flatten the curve and improve clinical outcomes. Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; a controlled, randomized trial of therapies that prevent infection, support immunity and a healthy inflammatory response; as well as an evaluation of different physiological and respiratory therapies to address the high mortality rates associated with complications of COVID-19 induced DIC and ARDS. 1. Diagnosis: to date, physical isolation (including those who test positive for exposure), distancing as well as handwashing have been mandated on a population wide basis to prevent the spread of disease. There are several key clinical symptoms which would however suggest a high likelihood of exposure necessitating immediate isolation. This would include the constellation of early prodromal symptoms of anosmia, hyposmia, and dysgeusia, along with a fever, sore throat, cough and shortness of breath. There are very few diseases that cause a sudden loss or decreased sense of smell and/or taste. According to the medical literature, approximately 5% of people exhibit functional anosmia primarily caused by senescence 36 , where 25% of people above the age of 50 have an impaired sense of smell 37 38 . Olfactory health can be a measure of the number of medications taken 39 , and also directly reflect the overall health of a person, where lowered olfactory abilities seem to be negatively associated with life expectancy and an increased risk of death 40 . This is primarily due to those patients with neurodegenerative diseases, especially Parkinson's, Alzheimer's disease or Lewy body dementia, who have olfactory loss early on in the course of their disorder, allowing a tentative diagnosis years prior to the arising of motor or cognitive disturbances 41 . Apart from neurodegenerative diseases, the three major causes of a loss of smell are trauma, rhinosinusitis/nasal polyps, and viral infections 41 . Although the prevalence rates of acute rhinosinusitis with symptoms of nasal obstruction/congestion or nasal discharge (anterior/posterior nasal drip) and facial pain/pressure can range from 6-15% and between 2.7-8% in Western and Asian populations respectively 42 , olfactory dysfunction linked to COVID-19 infection seems particular as it is not usually associated with rhinorrhea 43 which is part of the symptom complex of acute rhinosinusitis. Clinical studies from Asia did initially report rhinorrhea along with primary symptoms of a fever, sore throat, cough, dyspnea, sputum production, myalgia, arthralgia, headache, and diarrhea 44 46 , which have been shown to due to inflammation. For example, autoimmune diseases, e.g. Sjögren's syndrome and systemic lupus erythematosus (SLE), are known to affect taste function and are associated with the elevated levels of inflammatory cytokines interleukin (IL)-6 and interferon (IFN)-γ. 47 48 These are some of the same inflammatory cytokines seen in COVID-19 infection 20 , and the strong association between inflammation and taste disorders suggests that the new, sudden onset of this symptom in the setting of a viral pandemic would again imply coronavirus exposure where inflammation is playing a role in the pathogenesis of taste dysfunction. Immediate isolation at first onset of these symptoms, even if otherwise asymptomatic, could help flatten the cure and decrease widespread exposure. When these symptoms are considered in the setting of the constellation of fevers, sore throat, cough and or shortness of breath, with or without fatigue, headaches, myalgias and/or diarrhea, then the new onset of anosmia, hyposmia, and/or dysgeusia would help clinically to confirm exposure with a high likelihood of probability. These symptoms could be collected via an online questionnaire or digital app, as assessing clinical symptoms is a hallmark of medical diagnostic strategy. Previous research has demonstrated that selfreported symptoms can be reliable predictors of health outcomes, and poorer self-rated health is associated with elevated inflammatory markers among older adults 49 such as C-reactive protein and IL-6, the same inflammatory markers found in COVID-19. There is a long history of using validated self-report questionnaires for detecting/diagnosing medical and mental health conditions and quality of life issues in medicine, including but not limited to establishing a diagnosis of anxiety and clinical depression, gastrointestinal disorders including gastroesophageal reflux disease and dysphagia, peripheral artery disease, cancer care delivery, Lyme disease etc. 50 51 52 53 . Recently, an app was developed for clinical use by Israeli researchers, and has been instituted as a screening tool in Canada for COVID-19 54 . This app has the capability to monitor peoples' vital signs when they look on their smartphone screens and "triage nurses can check vital signs (heart rate, respiratory rate, and the blood's oxygen saturation) without touching patients; the condition of certain hospitalized patients can be monitored from their beds; and the vital signs of patients at home can be checked remotely" 54 . Similarly, Adaptive Biotechnologies Corp. and Microsoft have recently collaborated on mapping the immune system's response to COVID-19, using machine learning capabilities to sift through data on the body's T-cell receptor sequences, which get generated in response to antigens in the blood, which can then refine a "map" of those sequences by "matching trillions of T cells to the diseases they recognize" 55 . By combining validated screening questionnaires, apps and machine learning, we can identify early exposure and monitor vital signs from a distance. If some of the newer experimental protocols for COVID-19 infection involve the use of hydroxychloroquine and azithromycin, which have recently been published to be of potential benefit 56 , monitoring of cardiac arrythmias and can also be done digitally at home via KardiaMobile, a FDAcleared, clinical grade personal EKG monitor 57 . This would be important in those with cardiac risk factors and electrocardiograms can subsequently be stored on a smart phone and emailed to the physician for review. Prevention practices that need to be scientifically evaluated are the use of chloroquine, hydroxychloroquine, and ivermectin, which have been shown to have anti-viral effects against COVID 19 in vitro 58 59 60 61 as well as nutraceuticals including zinc, vitamin C and Beta glucan. Zincdeficiency can lead to an increased susceptibility to a variety of pathogens 62 , and zinc supplementation in healthy human subjects has been shown to lower oxidative stress related byproducts 63 , inhibit induction of TNF alpha and interleukin 1 beta 64 , protect against TNF-α-induced nuclear factor-κβ activation in isolated mononuclear cells 64 and regulate intracellular killing and cytokine production by macrophages 64 . In the immune system, the major role of vitamin C appears to be as an antioxidant, protecting the lungs and host cells against oxidative stress caused by infections 65 as well as helping to increase phagocyte function, the proliferation of T-lymphocytes and the production of interferon, while decreasing the replication of viruses 66 67 . In one study, Vitamin C was shown to shorten the length of the stay in the ICU and decrease the duration of mechanical ventilation for critically ill patients on respirators 68 . Finally, Beta glucans have been extensively published in the medical literature as having significant immunomodulatory properties 69 and double blind, placebo controlled trials have shown benefit in decreasing the severity of upper respiratory tract infections and lowering monocyte chemotactic protein-1 70 71 . For that reason, controlled clinical trials of hydroxychloroquine, ivermectin, and/or nutraceuticals including zinc, vitamin C and Beta glucans are needed to evaluate their effects for both prevention and diminishing the severity of clinical symptomatology post exposure. This is critically important since development of a safe and effective vaccine may be months to years away, and effective antiviral approaches could help flatten the curve and prevent infection. Randomized controlled trials of hydroxychloroquine, and or ivermectin, with or without the nutraceuticals zinc, vitamin C, and Beta glucans could be done in association with screening questionnaires/app's, to potentially detect early symptoms, monitor the clinical course from a distance without using precious hospital resources and upload treatment data to the cloud for large data computing, expediting results. 3. Treatment: no randomized, controlled trials have been reported to date to evaluate the efficacy of antiviral therapies in the treatment of COVID-19. Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies in China 72 , but hydroxychloroquine was found to be more potent than chloroquine in vitro 73 , and has less potential side effects 73 . An initial non-randomized small study done in France by Raoult et al showed benefit using hydroxychloroquine and azithromycin 56 and results of a larger clinical trial are pending. Other potential treatments being considered are ivermectin 61 , nitazoxanide 74 , remdesivir 75 , as well as repurposed drugs and nutritional supplements including but not limited to melatonin, mercaptopurine, and sirolimus 76 . Since none of these have yet undergone randomized, clinical trials, and no FDA treatments for COVID-19 are yet available, collecting data via an app and online questionnaire in those patients who have used these drug combinations 'off label' could be useful in directing clinical research. Inflammation and "cytokine storm syndrome" with hemophagocytic lymphohistiocytosis (HLH)/Macrophage Activation Syndrome (MAS) can lead to extreme morbidity and mortality. This is especially the case in those with certain comorbidities, including ARDS and multiorgan dysfunction with disseminated intravascular coagulation (DIC). ARDS is however the main cause of death in COVID-19 9 and the fundamental pathophysiology underlying many of the above complications is "cytokine storm syndrome" 77 19 . Control of cytokine production and unbridled inflammation which damages lung tissue and essential organs secondary to high levels of free radical/oxidative stress is essential. There are several potential mechanisms which can be helpful for lowering inflammation and need to be studied, apart from the effect of antiviral agents (hydroxychloroquine, chloroquine, remdesivir, nitazoxanide, ivermectin) and nutritional support (zinc, vitamin C, 3,6 beta glucan) previously described. Deficiency in red blood cell, serum and alveolar glutathione has been published in ARDS, viral and bacterial pneumonias, resulting from increased levels of free radical/oxidative stress 35 78 . Oxidative stress can trigger several biochemical pathways including NF-κB, which is a primary target for modulating inflammatory responses 79 . The transcription factor NF-κB regulates multiple aspects of innate and adaptive immune functions, is a pivotal mediator of inflammatory responses, induces the expression of various pro-inflammatory genes, including those encoding cytokines and chemokines, and also participates in inflammasome regulation 80 Inhibitors to block NFKappaB signaling include N-acetylcysteine (NAC) 82 , alpha lipoic acid 83 , as well as antioxidants like glutathione 84 . N-acetylcysteine and alpha lipoic acid can help increase production and regeneration of glutathione 85 86 , and deficiency in red blood cell, serum and alveolar glutathione has been found in ARDS 35 , as well as viral and bacterial pneumonias 87 , resulting from increased levels of free radical/oxidative stress 88 . A randomized controlled trial of blocking NFKappaB and cytokine formation using glutathione precursors (N-acetyl-cysteine [NAC] and alpha lipoic acid) as well as PO/IV glutathione should be performed, along with an evaluation of Nrf2 activators (curcumin, sulforaphane glucosinolate) which have been scientifically proven to lower inflammation 89 90 . The efficacy of glutathione therapy in rapidly relieving dyspnea associated with COVID-19 pneumonia was recently reported by Horowitz and Freeman in a peer-reviewed journal (under review). Since the Nrf2 pathway plays a pivotal role in inflammation 91 as does the NF-κB pathway and deficiencies in glutathione, these should be explored as part of a multifaceted approach to find effective treatments for COVID-19. High mortality rates from COVID-19 infection has been associated with abnormal coagulation parameters, thrombotic events and elevated levels of D-dimer with sepsis induced DIC 33 34 . Randomized controlled trials of using anticoagulant therapy with heparin is urgently required, especially in patients on ventilators who have met certain sepsis induced coagulopathy (SIC) criteria, since anticoagulation treatment has been published to decrease mortality from COVID-19 92 . The use of acetazolamide also needs to be explored with or without heparin, since increased oxygen delivery to vital organs via carbonic anhydrase inhibition may help improve hypoxia 93 , along with the drugs' ability to reverse metabolic alkalosis and facilitate weaning from mechanical ventilation. Although acetazolamide can improve arterial oxygen saturation (SaO2) by increasing ventilation, it is associated with an increased work and cost of breathing. Sildenafil could therefore also be used with acetazolamide to increase SaO2 possibly through a reduction in pulmonary hypertension and interstitial edema, helping to improve ventilation-perfusion matching 94 . Exposure to COVID-19 has high case fatality rates across countries worldwide 95 . Prevention is especially important since the US Center for Disease Control and Prevention (CDC) has estimated that hundreds of thousands of deaths will occur worldwide 96 , with the WHO estimating a global mortality rate greater than 5% 12 . Innovative solutions that have a low risk and high potential yield therefore require scientific validation. A three-part prevention, diagnostic and treatment plan is proposed for addressing the severe complications of COVID-19. Digital monitoring of symptoms to clinically diagnose early exposure and response to treatment; prevention with hydroxychloroquine and/or ivermetin as well as other medications and nutritional therapies that support a healthy immune response; treatment with anti-inflammatory therapies that block NFKappaB and activate Nrf2 pathways, as well as novel therapies that address COVID-19 pneumonia and ARDS with DIC, including anticoagulation with or without acetazolamide and sildenafil for those requiring respiratory support. These three hypothetical broad-based clinical interventions have been published in the medical literature to be of potential benefit in those with viral pneumonia and ARDS, with limited data available on their effects on COVID-19. We believe that it is urgent that these hypotheses be tested in a series of randomized, controlled trials to evaluate their ability to flatten the curve and decrease the presently high levels of morbidity and mortality associated with COVID-19. The views expressed are those of Dr Richard Horowitz, and do not represent the views of the Tick-Borne Disease Working Group, HHS the United States. Brief Review on COVID-19: The 2020 Pandemic Caused by SARS-CoV-2 History and Recent Advances in Coronavirus Discovery Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses. Cell Stress Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States Obesity and its Implications for COVID-19 Mortality COVID-19 and smoking: A systematic review of the evidence Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Analyzing the epidemiological outbreak of COVID-19: A visual exploratory data analysis approach Real estimates of mortality following COVID-19 infection Coronavirus Disease 2019: Resources. American Academy of Otolaryngology-Head and Neck Surgery Evaluation and Treatment Coronavirus (COVID-19) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet Molecular immune pathogenesis and diagnosis of COVID-19 Adult haemophagocytic syndrome -The Lancet Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis Pulmonary Involvement in Patients With Hemophagocytic Lymphohistiocytosis Hemophagocytic LymphohistiocytosisAn Update on Diagnosis and Pathogenesis The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome Hyperferritinemia in Hemophagocytic Lymphohistiocytosis: A Single Institution Experience in Pediatric Patients Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome The Definition and Risks of Cytokine Release Syndrome-Like in 11 COVID-19-Infected Pneumonia Critically Ill Patients: Disease Characteristics and Retrospective Analysis. Intensive Care and Critical Care Medicine Covid-19 in Critically Ill Patients in the Seattle Region -Case Series Pathogenesis of Acute Respiratory Distress Syndrome The Acute Respiratory Distress Syndrome: Pathogenesis and Treatment Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome Smell and taste disorders Prevalence of Olfactory Impairment in Older Adults Smell identification ability: changes with age A Study on the Frequency of Olfactory Dysfunction -Landis -2004 -The Laryngoscope -Wiley Online Library Odor identification and mortality in old age Olfactory Dysfunction: Common in Later Life and Early Warning of Neurodegenerative Disease Management of rhinosinusitis in adults in primary care Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore | Critical Care Medicine Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center Inflammation and taste disorders: mechanisms in taste buds Reduced preference for sucrose in autoimmune mice: a possible role of interleukin-6 Behavioral effects of infection with interferon-gamma adenovector Poorer self-rated health is associated with elevated inflammatory markers among older adults Assessment of patient-reported symptoms of anxiety The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery Empirical validation of the Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire for suspected Lyme disease Canadian hospital battles coronavirus outbreak with "revolutionary" app Adaptive Biotechnologies Using Microsoft Azure To Better Detect COVID-19 --Redmondmag Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Chloroquine for the 2019 novel coronavirus SARS-CoV-2 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro Zinc and immune function: the biological basis of altered resistance to infection Antioxidant effect of zinc in humans Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress Vitamin C and Infections Vitamin C may affect lung infections Vitamin C and Community-acquired Pneumonia Vitamin C may reduce the duration of mechanical ventilation in critically ill patients: a meta-regression analysis Beta Glucan: Supplement or Drug? From Laboratory to Influence of yeast-derived 1,3/1,6 glucopolysaccharide on circulating cytokines and chemokines with respect to upper respiratory tract infections Effects of Yeast (1,3)-(1,6)-Beta-Glucan on Severity of Upper Respiratory Tract Infections: A Double-Blind, Randomized, Placebo-Controlled Study in Healthy Subjects Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus Compassionate Use of Remdesivir for Patients with Severe Covid-19 Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2 The Interdependence of Lung Antioxidants and Antiprotease Defense in ARDS NF-κB as a target for modulating inflammatory responses NF-κB signaling in inflammation Janeway's Immunobiology, 8th edn. Garland N-Acetyl Cysteine Mediates Protection from 2-Hydroxyethyl Methacrylate Induced Apoptosis via Nuclear Factor Kappa B-Dependent and Independent Pathways: Potential Involvement of JNK Alpha-lipoic acid is a potent inhibitor of NF-kappa B activation in human T cells The glutaredoxin/glutathione system modulates NF-kappaB activity by glutathionylation of p65 in cinnamaldehyde-treated endothelial cells Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: A comparative crossover study α-Lipoic acid protects against the oxidative stress and cytotoxicity induced by cadmium in HepG2 cells through regenerating glutathione regulated by glutamate-cysteine ligase Role of glutathione in immunity and inflammation in the lung Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot study Immunomodulatory Effects of Curcumin Anti-Inflammatory Effect of Sulforaphane on LPS-Activated Microglia Potentially through JNK/AP-1/NF-κB Inhibition and Nrf2/HO-1 Activation Nrf2 signaling pathway: Pivotal roles in inflammation Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Acetazolamide during acute hypoxia improves tissue oxygenation in the human brain The effects of sildenafil and acetazolamide on breathing efficiency and ventilatory control during hypoxic exercise Cross-Country Comparison of Case Fatality Rates of COVID-19/SARS-COV-2. Osong Public Health Res Perspect COVID-19) Disclosure The authors declare no conflict of interest. The funders had no role in the design of the study We would like to thank the MSIDS Research Foundation (MRF) for providing us research grants for the publication of this study. Dr. Richard Horowitz is the guarantor of the contents of this manuscript. The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.